Inge Marie Svane
Researcher Next ID · RN-038586
Researcher · Biochemistry, Genetics and Molecular Biology
Copenhagen, Denmark
- Works count
- 826
- Citation count
- 24,449
- H-index
- 74
- i10-index
- 274
Research interests
Publications
Clinical advances and ongoing trials of mRNA vaccines for cancer treatment
The Lancet Oncology · 2022 · https://doi.org/10.1016/s1470-2045(22)00372-2
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2210233
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00065-6
Tertiary lymphoid structures improve immunotherapy and survival in melanoma
Nature · 2020 · https://doi.org/10.1038/s41586-019-1914-8
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30231-0
Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma
Nature Communications · 2017 · https://doi.org/10.1038/s41467-017-01460-0
Predictors of responses to immune checkpoint blockade in advanced melanoma
Nature Communications · 2017 · https://doi.org/10.1038/s41467-017-00608-2
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)70076-8
Current projects
No projects listed.